

**May 1, 2025**

## ***AmeriHealth Caritas Next Formulary Stelara Biosimilar Medications***

The FDA has recently approved several biosimilars for Stelara(ustekinumab). All biosimilars are FDA approved for the same indications as branded Stelara. Stelara will be removed from the AmeriHealth Caritas Next formulary as of **5/9/2025**. The following Stelara biosimilar medications will be added to the formulary at Tier 4 and require a prior authorization:

| <b>Proprietary Name</b> | <b>Non-proprietary name</b> | <b>Interchangeability with Stelara</b> |
|-------------------------|-----------------------------|--|
| Steqeyma                | (ustekinumab-stba)          | N                                      |
| Yesintek                | (ustekinumab-kfce)          | N                                      |
| Otulfi                  | (ustekinumab-aaaz)          | N                                      |
| Selarsdi                | (ustekinumab-aekn)          | Y                                      |

Please note that Selarsdi is interchangeable with Stelara. All biosimilars, including Selarsdi require a new prescription. A prescription for Stelara cannot be used to fill a biosimilar product even if it is interchangeable.

Please assess and if clinically appropriate, consider the use of one of the above biosimilars in place of branded Stelara for your patients in the future. If you have any questions, please reach out to AmeriHealth Caritas Next Pharmacy Services at 1-844-280-9131.

Thank you,

Pharmacy Services  
AmeriHealth Caritas Next